Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Annovis Bio

Anavex Life Sciences

Biogen

Prothena

Cassava Sciences Inc

An Alzheimer's Bubble That Was Well & Truly Burst May Be Blowing Up Again - Here's Why

INDIANAPOLIS, Nov. 9, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Wolfe Research Virtual Healthcare Conference on Thursday, Nov. 18, 2021. Jacob Van Naarden, CEO of Loxo Oncology at Lilly and president, Lilly Oncology; Mark Mintun, senior vice president, research and development – neuroscience, and president, Avid Radiopharmaceuticals; and David Hyman, M.D.

Lilly to Participate in Wolfe Research Virtual Healthcare Conference

Amgen

American States Water

Chevron

Duke Energy

Emerson Electric

Honeywell

Microsoft

Pinnacle West Capital

Target

Visa

Walgreens

Exxon Mobil

We provide a summary of upcoming ex-dividend dates in a quick reference table. The table includes relevant data and key statistics as well as the next payout and pay date.

Upcoming Ex-Dividend Dates: November 10-22, 2021

Incyte

INDIANAPOLIS, Nov. 9, 2021 /PRNewswire/ -- OLUMIANT ® (baricitinib) maintained a consistent safety profile in a long-term, integrated safety analysis of patients with rheumatoid arthritis (RA) who received OLUMIANT for 14,744 patient years of exposure, in line with previously published findings. Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) will present these results, along with real-world safety results from 3,445 patients with RA in Japan, at ACR Convergence 2021, the American College of Rheumatology's virtual annual meeting taking place November 3-9, 2021.

OLUMIANT® Long-Term Safety Profile Established Up to 9.3 Years in Integrated Analysis of More Than 3,700 Patients with Rheumatoid Arthritis

Ameriprise Financial

Franklin Resources

Blackrock Inc

Infosys

KLA-Tencor

Pfizer

T. Rowe Price Group

Taiwan Semiconductor Manufacturing

United Microelectronics

Releasing two top November stocks from the MDA Growth and Dividend Breakout monthly portfolio and two top samples from prior portfolios. Long-term dividend portfolios have a 1 year average weighted gain of +20.6%. The best gain is still from the May 2020 portfolio +87.5%.

V&M Breakouts: Top Growth And Dividend Stocks For November 2021

INGELHEIM, Germany & INDIANAPOLIS--(BUSINESS WIRE)--Empagliflozin shows consistent cardio-renal benefits in adults with heart failure with LVEF >40 percent regardless of chronic kidney disease status

Empagliflozin shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40 percent regardless of chronic kidney disease status

RIDGEFIELD, Conn. and INDIANAPOLIS, Nov. 5, 2021 /PRNewswire/ -- Jardiance® (empagliflozin) reduced the risk for the composite primary endpoint of cardiovascular death or hospitalization for heart failure and slowed kidney function decline in adults with heart failure with left ventricular ejection fraction (LVEF) over 40% regardless of chronic kidney disease status at baseline, according to findings from a new prespecified sub-analysis of the EMPEROR-Preserved® phase III trial.

Jardiance® shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40% regardless of chronic kidney disease status

The stock price of ​Eli Lilly has seen a rise of 15% over the last month, while it is up 6% in a week. There are a couple of factors that fueled this growth.

What's Happening With Eli Lilly Stock?

INDIANAPOLIS, Nov. 4, 2021 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), today announced that study investigators will present data from the pirtobrutinib development program at the American Society of Hematology (ASH) Annual Meeting to be held December 11-14, 2021 in Atlanta, GA and virtually. Pirtobrutinib is an investigational, highly selective, non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor.

Loxo Oncology at Lilly Announces Details of Presentations at the 2021 American Society of Hematology (ASH) Annual Meeting

Lilly reported solid growth, but its pipeline updates could be even more interesting.

What Investors Should Like About Eli Lilly's Q3 Update

Eli Lilly And Co (NYSE: LLY) traded higher Tuesday after the company announced it will supply 614,000 additional doses of bamlanivimab with etesevimab to the U.S. government for a total of $1.29 billion. Eli Lilly expects that the additional doses will increase revenue by $840 million and earnings by approximately 25 cents per share beyond the guidance that was issued during its most recent financial results.

Why Eli Lilly Shares Traded Higher Today

A prominent Wall Street firm thinks Eli Lilly and Co. ( LLY , Financial) hopes to scuttle the introduction of Biogen Inc.'s ( BIIB , Financial) recently approved Alzheimer's drug before it gains traction with its own treatment, according to an article by drug consulting firm Evaluate.

Eli Lilly's Alzheimer's Drug Could Be 'Game-Changer' for Company

INDIANAPOLIS, Nov. 2, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced an additional purchase by the U.S. government for bamlanivimab with etesevimab for administration together. This neutralizing antibody therapy is authorized for emergency use for the treatment of mild to moderate COVID-19 or for post-exposure prophylaxis of COVID-19 in certain individuals.

Lilly to supply 614,000 additional doses of bamlanivimab and etesevimab to the U.S. Government for the treatment or post-exposure prevention of COVID-19

INDIANAPOLIS, Nov. 1, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in Bernstein's Second Annual Operational Decisions Conference on Thursday, Nov. 4, 2021. Jake Van Naarden, CEO of Loxo Oncology at Lilly and president of Lilly Oncology; Mark Mintun, senior vice president, research and development – neuroscience, and president, Avid Radiopharmaceuticals; and Jamie Croaning, global development leader – tirzepatide, will participate in a virtual fireside chat at 12:30 p.m.

Lilly to Participate in Bernstein's Second Annual Operational Decisions Conference

INDIANAPOLIS, Oct. 28, 2021 /PRNewswire/ -- Today, overall survival (OS) data from Eli Lilly and Company's (NYSE: LLY) Verzenio® (abemaciclib) Phase 3 monarchE study were published in a Letter to the Editor in the Annals of Oncology. These OS data, while immature, have been published to address questions regarding the recent approval by the U.S. Food and Drug Administration (FDA) in a subgroup of the population studied in the monarchE trial.

Additional Verzenio® (abemaciclib) Phase 3 monarchE Trial Data Published in the Annals of Oncology

AbbVie

Fidelity MSCI Health Care ETF

Gilead Sciences

iShares U.S. Healthcare ETF

Johnson & Johnson

Merck

UnitedHealth Group

Vanguard Health Care ETF

Health Care Select Sector SPDR Fund

The healthcare sector is expected to witness substantial earnings growth of 17.5% in the third quarter.

Healthcare ETFs in Focus as Q3 Earnings Unfold

It's an exciting if turbulent, and rather cutthroat, time in the world of Alzheimer's drug research. In June, the FDA greenlit Biogen's.

Eli Lilly Pitches Alzheimer Drug to the FDA, Aiming to Leapfrog Biogen

Eli Lilly is one of the highest quality pharmaceutical companies one can buy today.

Eli Lilly: Quality Wins The Race

Novartis

On Monday, Eli Lilly And Co (NYSE:LLY) and Novartis AG (OTCMKTS:NVSEF) shares edged higher after announcing their most recent quarterly results. Eli Lilly's revenue and earnings missed expectations while Novartis beat on earnings and matched top-line estimates.

Is Eli Lilly or Novartis the better buy after Q3 results?

Eli Lilly and Company (LLY) CEO David Ricks on Q3 2021 Results - Earnings Call Transcript

Lilly (LLY) delivered earnings and revenue surprises of -2.02% and 1.73%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Eli Lilly (LLY) Misses Q3 Earnings Estimates

The Case-Shiller Home Price Index for August came in at +19.8%, right in-line with what analysts were looking for.

Home Prices Stay "Lofty;" UPS Beats, Lilly Mixed

Eli Lilly (LLY) reports mixed third-quarter results and raises its 2021 sales forecast.

Eli Lilly (LLY) Q3 Earnings Miss, COVID Drugs Drive Sales

Eli Lilly & Co (NYSE: LLY) said its earnings in the fiscal third quarter fell shy of Wall Street estimates. Shares, however, remained stable in premarket trading as revenue came in better-than-expected.

Eli Lilly CEO defends earnings miss in fiscal Q3

Eli Lilly And Co (NYSE: LLY) has posted Q3 sales of $6.77 billion, beating the consensus of $5.70 billion and increasing 18% Y/Y. Higher sales were driven by a 17% increase in volume and a 1% increase due to the favorable impact of foreign exchange rates.

News for Eli Lilly Stock (LLY)